The widespread acceptance of the so-called GLP-1 drugs, Zepbound by Eli Lilly and Wegovy by Novo Nordisk, for weight loss has created a game-changing dynamic for the overall health of the 72% of ...

Surgical patients may still have leftovers in their system even after a standard fast, potentially increasing the chance of a serious complication.

President Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ending birthright citizenship, are quickly slapped down in ...

A new poll from The Associated Press-NORC Center for Public Affairs Research looks at what U.S. adults think about weight-loss drugs like Ozempic or Wegovy. (AP Video: Laura Bargfeld) ...

Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ending birthright citizenship, ...

The Medicines and Healthcare Products Regulatory Agency (MHRA) has ruled that warnings about the risk should now be added to ...

GLP1-based obesity medicines, such as Ozempic and Wegovy, have surged in popularity and become the subject of intense public ...

A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 ...

An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.